


DETECT
OMICRON, DELTA, BETA

EurobioPlex SARS-CoV-2 Fast-SVD

Real time RT-PCR for qualitative detection¹
of SARS-COV-2 and its VOCs

DETECTION AND SCREENING



Quick result: < 50 min²

Endogenous IC³

Detection and typing in a single well³

1. For more information, please refer to the " Purpose of the system " paragraph of the user manual.
2. For more information, please refer to the " Procedure " paragraph of the user manual.
3. For more information, please refer to the " Principle of detection " paragraph of the user manual.

17/01/2022



CLINICAL CONTEXT

The SARS-CoV-2 virus appeared in China at the end of 2019, in the city of Wuhan. It belongs to the family of Coronaviridae and subgenus Sarbecovirus. Since then, other genetic variants of concern (VOCs) have emerged. These variants carry mutations that are associated with increased transmissibility (L452R) or possible immune escape (L452R, E484K and E484Q).⁴

In terms of clinical presentation, the symptoms range in their severity from mild to severe.⁵

DIAGNOSTIC

The diagnosis of SARS-CoV-2 infection today is based primarily on the presence of detection of viral RNA by real-time RT-PCR. Standard run times for RT-PCR reactions are 90 minutes, with variant detection performed as a reflex test, or via sequencing. The EBX-047 assay detects original Sars-cov-2 and key variants in the same run, reducing turn around time.⁶

CHARACTERISTICS

Principle of the test	Detection of the SARS-CoV-2 virus and selected SNPs
Technology	Real time RT-PCR
Target genes ²	SARS CoV-2 RdRp 1 and RdRp 2 genes; Mutations E484K, K417N, L452R
Sample type ¹	Nasopharyngeal swabs
Controls included ³	Positive, negative and endogenous controls
Run time	< 50 min ³

PERFORMANCES⁷

Sensitivity

> 99%

Specificity

> 99%

Detection threshold : depending on the target.

Reference	Description	Format
EBX-047	EurobioPlex SARS-CoV-2 Fast-SVD Real time RT-PCR	92 / 192 / 600 tests

4. Public Health France. 2021. Variant circulation: new screening strategy by looking for mutations of interest. [2021/06/10]. <https://www.santepubliquefrance.fr/les-actualites/2021/circulation-des-variants-nouvelle-strategie-de-criblage-par-la-recherche-de-mutations-d-interet>

5. For more information, please refer to the "General information" paragraph of the user manual

6. Institut Pasteur. 2021. COVID-19 DISEASE (NEW CORONAVIRUS). [2021/01/13].

<https://www.pasteur.fr/fr/centre-medical/ches-maladies/maladie-covid-19-nouveau-coronavirus>

7. For more information, please refer to the "Performance analysis" paragraph of the user manual.